ALPMs top line declined 14% YoY, EBITDA margin came in at 20.4% (-1689bps YoY) and PAT stood at Rs 1.2bn (down 58%YoY) on a high base of 2QFY16 which included substantial gAbilify sales. However, sequential numbers made for better reading with ALPM effecting a revenue growth of 20% on the back of better season for acute products in India business and improved traction in the US base business.